REG - Medica Group PLC - Result of Annual General Meeting

MedicaAnnouncement

30/06/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230630:nRSd5790Ea&default-theme=true

RNS Number : 5790E  Medica Group PLC  30 June 2023

30 June 2023

 

Medica Group Plc

 

Result of Annual General Meeting

 

 

Medica Group PLC (LSE:MGP, "Medica" or the "Company"), an international
provider of high-quality telemedicine services, announces that, at its Annual
General Meeting held at 10.30am today at the offices of DLA Piper, 160
Aldersgate Street, London EC1A 4HT, all resolutions put to the meeting were
duly passed.

 

Details of the voting are as follows:

 

 Resolution                                                                                             For/         %            Against             %         Total       Withheld

                                                                                                        Discretion   For/         (Number of votes)   Against   votes       (Number of votes)

                                                                                                        (Number of   Discretion

                                                                                                        votes)
 Ordinary Business
 Ordinary Resolutions
 1.                       To receive and adopt the annual report, accounts and the auditor's report     66,479,561   100.00       0                   0.00      66,479,561  249,911
 2.                       To approve the Directors' Remuneration Report                                 37,121,768   57.83        27,067,040          42.17     64,188,808  2,540,664
 3.                       To declare a final dividend                                                   See note below*
 4.                       To re-appoint Grant Thornton UK LLP as auditors                               66,081,401   99.40        399,054             0.60      66,480,455  249,017
 5.                       To authorise the Directors to determine the remuneration of the auditors      66,716,249   99.98        10,759              0.02      66,727,008  2,464
 6.                       To re-elect Roy Davis as a Director                                           65,870,471   99.21        526,381             0.79      66,396,852  332,620
 7.                       To re-elect Barbara Moorhouse as a Director                                   66,204,304   99.22        522,538             0.78      66,726,842  2,630
 8.                       To re-elect Joanne Easton as a Director                                       66,204,415   99.21        524,189             0.79      66,728,604  868
 9.                       To re-elect Dr Junaid Bajwa as a Director                                     65,093,295   97.92        1,384,696           2.08      66,477,991  251,481
 10.                      To re-elect Stuart Quin as a Director                                         66,726,029   100.00       813                 0.00      66,726,842  2,630
 11.                      To re-elect Richard Jones as a Director                                       66,477,880   100.00       111                 0.00      66,477,991  251,481
 Special Business
 Ordinary resolution
 12.                      General authority to allot shares pursuant to Section 551 Companies Act 2006  66,717,902   99.99        8,940               0.01      66,726,842  2,630
 Special resolutions
 13.                      Standard pre-emption disapplication                                           64,925,423   97.30        1,800,717           2.70      66,726,140  3,332
 14.                      Additional pre-emption disapplication for the purpose of financing an         64,672,763   96.92        2,053,377           3.08      66,726,140  3,332
                          acquisition or other capital investment
 15.                      Authority to make market purchases of up to 12,288,363 shares                 65,844,437   99.62        248,149             0.38      66,092,586  636,886
 16.                      To authorise general meetings to be held on 14 clear days' notice             66,165,995   99.16        562,609             0.84      66,728,604  868

 

* As previously communicated by an RNS announcement this morning, the
resolution to declare a final dividend for the year ended 31 December 2022 of
1.88 pence per share ("2022 Final Dividend") (Resolution 3) was withdrawn
prior to, and was not presented to, the AGM. This will ensure shareholders
receive 212 pence per share in full without any reduction in respect of the
previously proposed 2022 Final Dividend as opposed to two separate payments
and in accordance with the terms of the recommended cash acquisition for the
Company by Moonlight Bidco Limited (once effected).

 

 

For further information, please contact:

 

 Medica Group Plc:                        +44 (0)33 33 111 222

 Stuart Quin, Chief Executive Officer

 Richard Jones, Chief Financial Officer

 FTI Consulting                           +44 (0)20 3727 1000

 Victoria Foster Mitchell

 Sam Purewal

 Liberum (Joint Broker)                   +44 (0)20 3100 2000

 Phil Walker

 Richard Lindley

 Numis (Joint Broker)                     +44 (0)20 7260 1000

 Freddie Barnfield

 Duncan Monteith

 Euan Brown

 

About Medica Group PLC

 

Medica (LSE:MGP) is an international provider of high-quality telemedicine
services. It is the market leader in teleradiology in the UK and Ireland,
working with more than 100 NHS Trusts and HSE hospitals in Ireland, in
addition to private hospitals, insurance groups and diagnostic imaging
companies. Its network of consultant radiologists, radiographers and
specialist doctors interpret and report MRI, CT, ultrasound and X-ray images
on behalf of healthcare providers, using Medica's bespoke, secure technology
platform for fast and responsive delivery. The company's core services include
NightHawk, an urgent, out-of-hours offering available to clients 24/7 with
dedicated pathways for stroke and major trauma, and Elective, for routine
reporting.

 

In Ireland, Medica carries out patient scanning, as well as reporting, and
runs a diabetic retinopathy screening programme for the National Screening
Service. Through its US business, RadMD, Medica provides global pharmaceutical
and biotech companies, as well as contract research organisations with
specialist imaging services for clinical trials.

 

For more information please visit: www.medicagroupplc.com
(http://www.medicagroupplc.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGWPURCQUPWGUU